Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs
作者： Asif Anwar , Imran John Anwar , Patrice Delafontaine
DOI: 10.1016/J.TCM.2015.03.006
关键词: Drug 、 Medicine 、 Cardiovascular outcomes 、 Prostaglandin 、 Pharmacology 、 Clinical trial 、 Cyclooxygenase 、 Adverse effect 、 Pathophysiology 、 Non steroidal anti inflammatory
摘要: Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most frequently used medications. NSAIDs profoundly modify prostaglandin homeostasis through inhibition enzyme, cyclooxygenase (COX), especially COX-2. COX-2 is associated with adverse cardiovascular outcomes as demonstrated by recent trials using this type drug. This review explores latest available data, including recent, randomized, clinical trials, controversies, and pathophysiology effects COX-inhibition.
tcmonline.org
elsevier.com参考文章(79)
IA Reilly, GA FitzGerald, Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. ,vol. 69, pp. 180- 186 ,(1987) , 10.1182/BLOOD.V69.1.180.BLOODJOURNAL691180
Robert Langenbach, Charles Loftin, Christopher Lee, Howard Tiano, Cyclooxygenase knockout mice: Models for elucidating isoform-specific functions Biochemical Pharmacology. ,vol. 58, pp. 1237- 1246 ,(1999) , 10.1016/S0006-2952(99)00158-6
Sharon Ann Hunt, None, ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Journal of the American College of Cardiology. ,vol. 46, pp. 1116- 1143 ,(2005) , 10.1016/J.JACC.2005.08.022
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials The Lancet. ,vol. 382, pp. 769- 779 ,(2013) , 10.1016/S0140-6736(13)60900-9
Nicholas S Kirkby, Martina H Lundberg, Louise S Harrington, Philip DM Leadbeater, Ginger L Milne, Claire MF Potter, Malak Al-Yamani, Oladipupo Adeyemi, Timothy D Warner, Jane A Mitchell, None, Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 109, pp. 17597- 17602 ,(2012) , 10.1073/PNAS.1209192109
Matthew C Becker, Thomas H Wang, Lisa Wisniewski, Kathy Wolski, Peter Libby, Thomas F Lüscher, Jeffrey S Borer, Alice M Mascette, M Elaine Husni, Daniel H Solomon, David Y Graham, Neville D Yeomans, Henry Krum, Frank Ruschitzka, A Michael Lincoff, Steven E Nissen, Precision Investigators, None, Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. American Heart Journal. ,vol. 157, pp. 606- 612 ,(2009) , 10.1016/J.AHJ.2008.12.014
Francesco Cipollone, Maria Luigia Fazia, COX-2 and atherosclerosis. Journal of Cardiovascular Pharmacology. ,vol. 47, ,(2006) , 10.1097/00005344-200605001-00006
Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation. ,vol. 107, pp. 1479- 1485 ,(2003) , 10.1161/01.CIR.0000056530.03783.81
Inmaculada del Rincón, Gregory L. Freeman, Roy W. Haas, Daniel H. O'Leary, Agustín Escalante, Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis & Rheumatism. ,vol. 52, pp. 3413- 3423 ,(2005) , 10.1002/ART.21397
Anthony G Johnson, Tuan V Nguyen, Richard O Day, Do Nonsteroidal Anti-inflammatory Drugs Affect Blood Pressure? A Meta-Analysis Annals of Internal Medicine. ,vol. 121, pp. 289- 300 ,(1994) , 10.7326/0003-4819-121-4-199408150-00011